Relationship between gene expression patterns from nasopharyngeal swabs and serum biomarkers in patients hospitalized with COVID-19, following treatment with the neutralizing monoclonal antibody bamlanivimab.
Autorzy:
Sims JT; Eli Lilly and Company, Lilly Corporate Center, 893 S Delaware St., Indianapolis, IN, 46285, USA. Poorbaugh J; Eli Lilly and Company, Lilly Corporate Center, 893 S Delaware St., Indianapolis, IN, 46285, USA. Chang CY; Eli Lilly and Company, Lilly Corporate Center, 893 S Delaware St., Indianapolis, IN, 46285, USA. Holzer TR; Eli Lilly and Company, Lilly Corporate Center, 893 S Delaware St., Indianapolis, IN, 46285, USA. Zhang L; Eli Lilly and Company, Lilly Corporate Center, 893 S Delaware St., Indianapolis, IN, 46285, USA. Engle SM; Eli Lilly and Company, Lilly Corporate Center, 893 S Delaware St., Indianapolis, IN, 46285, USA. Beasley S; Eli Lilly and Company, Lilly Corporate Center, 893 S Delaware St., Indianapolis, IN, 46285, USA. Doman TN; Eli Lilly and Company, Lilly Corporate Center, 893 S Delaware St., Indianapolis, IN, 46285, USA. Naughton L; Eli Lilly and Company, Lilly Corporate Center, 893 S Delaware St., Indianapolis, IN, 46285, USA. HiggsRE; Eli Lilly and Company, Lilly Corporate Center, 893 S Delaware St., Indianapolis, IN, 46285, USA. Kallewaard N; Eli Lilly and Company, Lilly Corporate Center, 893 S Delaware St., Indianapolis, IN, 46285, USA. Benschop RJ; Eli Lilly and Company, Lilly Corporate Center, 893 S Delaware St., Indianapolis, IN, 46285, USA. .
Insights into adult atopic dermatitis heterogeneity derived from circulating biomarker profiling in patients with moderate-to-severe disease.
Autorzy:
Sims JT; Eli Lilly and Company, Indianapolis, IN, USA. Chang CY; Eli Lilly and Company, Indianapolis, IN, USA. HiggsRE; Eli Lilly and Company, Indianapolis, IN, USA. Engle SM; Eli Lilly and Company, Indianapolis, IN, USA. Liu Y; Eli Lilly and Company, Indianapolis, IN, USA. Sissons SE; Eli Lilly and Company, Indianapolis, IN, USA. Rodgers GH; Eli Lilly and Company, Indianapolis, IN, USA. Simpson EL; Department of Dermatology, Oregon Health & Science University, Portland, OR, USA. Silverberg JI; Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA. Forman SB; Forward Clinical Trials, Inc, Tampa, FL, USA. Janes JM; Eli Lilly and Company, Indianapolis, IN, USA. Colvin SC; Eli Lilly and Company, Indianapolis, IN, USA. Guttman-Yassky E; Department of Dermatology and the Laboratory for Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Pokaż więcej
Źródło:
Experimental dermatology [Exp Dermatol] 2021 Nov; Vol. 30 (11), pp. 1650-1661. Date of Electronic Publication: 2021 Jun 09.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Validation Study
A Bayesian gene network reveals insight into the JAK-STAT pathway in systemic lupus erythematosus.
Autorzy:
Li Y; Eli Lilly and Company, Indianapolis, Indiana, United States of America. HiggsRE; Eli Lilly and Company, Indianapolis, Indiana, United States of America. Hoffman RW; Eli Lilly and Company, Indianapolis, Indiana, United States of America. Dow ER; Eli Lilly and Company, Indianapolis, Indiana, United States of America. Liu X; Eli Lilly and Company, Indianapolis, Indiana, United States of America. Petri M; Hopkins Lupus Center, John Hopkins University, Baltimore, Maryland, United States of America. Wallace DJ; David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America. Dörner T; Charité University Hospitals, Berlin, Germany. Eastwood BJ; Eli Lilly and Company, Indianapolis, Indiana, United States of America. Miller BB; Eli Lilly and Company, Indianapolis, Indiana, United States of America. Liu Y; Eli Lilly and Company, Indianapolis, Indiana, United States of America.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2019 Dec 02; Vol. 14 (12), pp. e0225651. Date of Electronic Publication: 2019 Dec 02 (Print Publication: 2019).
Assessment and Clinical Relevance of Serum IL-19 Levels in Psoriasis and Atopic Dermatitis Using a Sensitive and Specific Novel Immunoassay.
Autorzy:
Konrad RJ; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 46285, USA. HiggsRE; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 46285, USA. Rodgers GH; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 46285, USA. Ming W; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 46285, USA. Qian YW; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 46285, USA. Bivi N; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 46285, USA. Mack JK; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 46285, USA. Siegel RW; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 46285, USA. Nickoloff BJ; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 46285, USA. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2019 Mar 26; Vol. 9 (1), pp. 5211. Date of Electronic Publication: 2019 Mar 26.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Multicenter Study
Quantitative measurement of intact alpha-synuclein proteoforms from post-mortem control and Parkinson's disease brain tissue by intact protein mass spectrometry.
Autorzy:
Kellie JF; GSK, 709 Swedeland Road, King of Prussia, PA. HiggsRE; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN. Ryder JW; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN. Major A; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN. Beach TG; Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, Sun City, AZ. Adler CH; Department of Neurology, Mayo Clinic Arizona, Scottsdale, AZ. Merchant K; TransThera Consulting Co., Indianapolis, IN. Knierman MD; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2014 Jul 23; Vol. 4, pp. 5797. Date of Electronic Publication: 2014 Jul 23.
Typ publikacji:
Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Identification of druggable cancer driver genes amplified across TCGA datasets.
Autorzy:
Chen Y; Department of Oncology, Eli Lilly and Company, Indianapolis, Indiana, United States of America. McGee J; Department of Oncology, Eli Lilly and Company, Indianapolis, Indiana, United States of America. Chen X; Department of Oncology, Eli Lilly and Company, Indianapolis, Indiana, United States of America. Doman TN; Department of Oncology, Eli Lilly and Company, Indianapolis, Indiana, United States of America. Gong X; Department of Oncology, Eli Lilly and Company, Indianapolis, Indiana, United States of America. Zhang Y; Department of Oncology, Eli Lilly and Company, Indianapolis, Indiana, United States of America. Hamm N; Department of Oncology, Eli Lilly and Company, Indianapolis, Indiana, United States of America. Ma X; Department of Oncology, Eli Lilly and Company, Indianapolis, Indiana, United States of America. HiggsRE; Department of Oncology, Eli Lilly and Company, Indianapolis, Indiana, United States of America. Bhagwat SV; Department of Oncology, Eli Lilly and Company, Indianapolis, Indiana, United States of America. Buchanan S; Department of Oncology, Eli Lilly and Company, Indianapolis, Indiana, United States of America. Peng SB; Department of Oncology, Eli Lilly and Company, Indianapolis, Indiana, United States of America. Staschke KA; Department of Oncology, Eli Lilly and Company, Indianapolis, Indiana, United States of America. Yadav V; Department of Oncology, Eli Lilly and Company, Indianapolis, Indiana, United States of America. Yue Y; Department of Oncology, Eli Lilly and Company, Indianapolis, Indiana, United States of America. Kouros-Mehr H; Department of Oncology, Eli Lilly and Company, Indianapolis, Indiana, United States of America.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2014 May 29; Vol. 9 (5), pp. e98293. Date of Electronic Publication: 2014 May 29 (Print Publication: 2014).
Quantitative Proteomics via High Resolution MS Quantification: Capabilities and Limitations.
Autorzy:
HiggsRE; Global Discovery and Development Statistics, Lilly Research Laboratories, Indianapolis, IN 46285, USA ; Lilly Corporate Center, DC 0720, Indianapolis, IN 46285, USA. Butler JP Han B Knierman MD
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
